Rapid Near Point-of-Care Assay for HLA-B*57:01 Genotype Associated with Severe Hypersensitivity Reaction to Abacavir.

Objective null The nucleoside reverse transcriptase inhibitor abacavir is used commonly to treat young children with HIV infection and is a component of the fixed-dose-combination Triumeq®. Abacavir can trigger a severe hypersensitivity reaction in people who are homozygous or heterozygous for HLA-B*57:01. Testing for HLA-B*57:01 prior to abacavir initiation is standard-of-care in high-resource settings, but current tests are costly or difficult...